Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($2.11) by $0.78, MarketWatch Earnings reports. Enanta Pharmaceuticals had a negative net margin of 163.87% and a negative return on equity of 46.77%. During the same quarter in the previous year, the firm posted ($1.27) EPS.
Enanta Pharmaceuticals Stock Performance
NASDAQ:ENTA opened at $8.94 on Tuesday. The stock has a 50-day simple moving average of $10.07 and a 200-day simple moving average of $16.97. The stock has a market cap of $188.23 million, a P/E ratio of -1.42 and a beta of 0.48. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $62.06.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at $225,000. Tudor Investment Corp Et Al acquired a new position in Enanta Pharmaceuticals in the second quarter valued at $222,000. Comerica Bank purchased a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $170,000. Deutsche Bank AG lifted its holdings in shares of Enanta Pharmaceuticals by 15.4% in the 3rd quarter. Deutsche Bank AG now owns 10,365 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 1,383 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $115,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Five stocks we like better than Enanta Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- The only two airline stocks worth buying: One is a Goldman pick
- How to Calculate Return on Investment (ROI)
- Ride the momentum: Apparel stocks soaring at 52-week highs
- Financial Services Stocks Investing
- Safeguard your portfolio with these three bargain stocks
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.